ReviewClinical and molecular hepatology2022

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review.

Lei Miao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.